LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTCBB:IMUC) (“IMUC”) announced today that it has named C. Kirk Peacock to serve as its Interim President. Mr. Peacock, who has served on a part-time basis as IMUC’s Chief Financial Officer since January 2006, will also now serve as IMUC’s Interim President on a part-time basis. “We are pleased that Kirk Peacock has agreed to serve on an interim basis as our President,” said Dr. John Yu, IMUC’s Chairman of the Board. “We have launched an aggressive search to hire a full-time Chief Executive Officer with expertise and a proven track record of success in managing an early stage biopharmaceutical company like ours.”
